Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | PRKACA | P17612 | 1/20 | 0.33 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.33 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.33 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.33 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.33 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.33 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.33 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 3/20 | 0.32 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2776239 | 1.00 | LMNA (0.35) | LMNAHRH3ROCK1ROCK2PRKACA | |
| SCHEMBL2776383 | 1.00 | LMNA (0.35) | LMNAHRH3ROCK1ROCK2PRKACA | |
| SCHEMBL2780141 | 0.89 | MAOB (0.35) | LMNAHRH3ROCK1ROCK2PRKACA | |
| SCHEMBL2451971 | 0.89 | MAOB (0.35) | LMNAHRH3ROCK1ROCK2PRKACA | |
| SCHEMBL2451965 | 0.89 | MAOB (0.35) | LMNAHRH3ROCK1ROCK2PRKACA | |
| SCHEMBL2778822 | 0.89 | MAOB (0.35) | LMNAHRH3ROCK1ROCK2PRKACA | |
| SCHEMBL2451967 | 0.89 | MAOB (0.35) | LMNAHRH3ROCK1ROCK2PRKACA | |
| SCHEMBL2778825 | 0.89 | MAOB (0.35) | LMNAHRH3ROCK1ROCK2PRKACA | |
| SCHEMBL2454008 | 0.89 | LMNA (0.35) | LMNAHRH3ROCK1ROCK2PRKACA | |
| SCHEMBL2454011 | 0.89 | LMNA (0.35) | LMNAHRH3ROCK1ROCK2PRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2364088-B1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN IDEC INC (US) | 2014-04-16 | — | — | EP | disclosed |
| US-8546359-B2 | Bicyclic aryl sphingosine 1-phosphate analogs | BIOGEN IDEC MA INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20130059821-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN MA INC. | 2013-03-07 | — | — | US | disclosed |
| US-8269043-B2 | Bicyclic aryl sphingosine 1-phosphate analogs | BIOGEN IDEC MA INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20100160258-A1 | Bicyclic aryl sphingosine 1-phosphate analogs | BIOGEN IDEC MA INC. (US) | 2010-06-24 | — | — | US | disclosed |
| WO-2010051030-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN IDEC MA INC. (US) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160258-A1 | Bicyclic aryl sphingosine 1-phosphate analogs | S1PR1, S1PR3, S1PR4 | LMNA 3016/4885HRH3 613/4885ROCK1 1397/4885 |
| US-20130059821-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | S1PR1, S1PR2, S1PR3 | LMNA 2435/4885HRH3 995/4885ROCK1 2949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.